Risperidone treatment in 12 children with developmental disorders and attention-deficit/hyperactivity disorder

Area of Science:

• Child and Adolescent Psychiatry
• Neurodevelopmental Disorders
• Pharmacological Interventions

Background:

• Developmental disorders and associated behavioral problems, including ADHD, present significant challenges in child psychiatry.
• Novel antipsychotic medications are being explored for efficacy in pediatric populations.
• Evaluating risperidone's safety and effectiveness in children with developmental disorders and behavioral issues is crucial.

Purpose of the Study:

• To assess the safety and efficacy of risperidone in pediatric patients diagnosed with developmental disorder and attention-deficit/hyperactivity disorder (ADHD).
• To evaluate risperidone's impact on disruptive behaviors, particularly aggression, in this population.

Main Methods:

• An open clinical study involving 12 pediatric patients (ages 4-14) with diagnosed developmental disorder and ADHD.
• Treatment duration extended up to 2 years with daily risperidone doses of 1-3 mg.
• Data collection occurred between December 2002 and December 2004.

Main Results:

• A positive clinical response, as measured by the Clinical Global Impressions-Improvement scale, was observed in 9 out of 12 patients within 3 months.
• Risperidone was generally well-tolerated by all participants.
• Sedation was the most frequent side effect, leading to dose reduction in two patients but not treatment cessation.

Conclusions:

• Risperidone demonstrates potential as an effective treatment for children and adolescents experiencing developmental disorders and disruptive behaviors.
• The findings suggest a favorable safety profile for risperidone in this pediatric cohort.
• Further research may support risperidone's role in managing complex behavioral issues in developmental disorders.